Cannabidiol
The most studied non-psychoactive cannabinoid with broad therapeutic potential
Cannabidiol (CBD) is the second most abundant cannabinoid in cannabis and the most studied non-psychoactive compound in the plant. It has received FDA approval for epilepsy treatment and has demonstrated efficacy across anxiety, inflammation, neuroprotection, and pain in clinical and preclinical research.
Primary Receptors & Targets
CBD's pharmacology is notably complex — it does not bind directly to CB1 or CB2 receptors with high affinity, which explains its lack of psychoactivity. Instead, CBD acts through multiple molecular targets simultaneously.
Its primary anxiolytic and antidepressant effects are mediated through agonism at 5-HT1A serotonin receptors — the same receptors targeted by buspirone and SSRIs. CBD also inhibits the enzyme FAAH (fatty acid amide hydrolase), which breaks down anandamide (the endogenous "bliss" cannabinoid), effectively raising anandamide levels throughout the body.
CBD's anticonvulsant effects involve modulation of voltage-gated sodium channels and GPR55 receptor antagonism. Its anti-inflammatory effects involve inhibition of COX-2 and modulation of NF-κB signaling. Its neuroprotective effects involve antioxidant activity and mitochondrial protection.
This multi-target pharmacology makes CBD difficult to study with single-mechanism models but may explain its broad therapeutic profile.
FDA-approved as Epidiolex; multiple Phase III RCTs demonstrate 40–50% seizure reduction.
2025 JAMA Psychiatry RCT: 300mg/day produced significant HAM-A reduction vs. placebo (p<0.001).
Multiple RCTs show efficacy for neuropathic and inflammatory pain; COX-2 inhibition confirmed in vitro.
Open-label and small RCT data support reduction in PTSD symptom severity and nightmare frequency.
Higher doses (150–300mg) improve sleep quality; mechanism likely via anxiolytic rather than direct sedation.
Early clinical data suggest CBD reduces cue-induced craving in opioid and cannabis use disorder.
Small RCTs show antipsychotic effects comparable to amisulpride with fewer side effects.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
JAMA Psychiatry
Randomized controlled trial (n=284): 300mg/day CBD produced 54% responder rate vs. 31% placebo over 12 weeks.
New England Journal of Medicine
CBD reduced seizure frequency by 39% in Dravet syndrome patients vs. 13% placebo (p<0.001).
Pharmacology & Pharmacy
Full-spectrum CBD showed dose-dependent anti-inflammatory response; CBD isolate showed bell-shaped curve, suggesting entourage effect.
American Journal of Psychiatry
CBD (400–800mg) significantly reduced cue-induced craving and anxiety in heroin-abstinent individuals.
CBD was first isolated from cannabis in 1940 by American chemist Roger Adams at the University of Illinois, though its structure was not fully elucidated until 1963 by Israeli chemist Raphael Mechoulam — the same researcher who would later identify THC and describe the endocannabinoid system. For decades, CBD was overshadowed by THC research. The modern CBD era began in 2013 when CNN's documentary on Charlotte Figi — a child with Dravet syndrome whose seizures were dramatically reduced by a high-CBD cannabis extract — brought CBD to mainstream attention. The subsequent FDA approval of Epidiolex in 2018 marked the first cannabis-derived pharmaceutical approved in the United States.
Unlike THC, CBD does not directly activate CB1 or CB2 receptors. Instead, it acts as a negative allosteric modulator of CB1 receptors — meaning it can reduce THC's psychoactive effects when both compounds are present. This is the pharmacological basis for the clinical observation that CBD "takes the edge off" THC. CBD also raises endogenous cannabinoid levels by inhibiting FAAH, the enzyme that breaks down anandamide. This indirect enhancement of the endocannabinoid system may contribute to CBD's broad therapeutic profile without the direct receptor activation that produces THC's psychoactive effects.
The consumer CBD market is characterized by significant quality variability. A 2017 JAMA study found that 69% of CBD products were mislabeled — with actual CBD content deviating more than 10% from label claims in most products tested. This variability makes it difficult for consumers to achieve consistent therapeutic effects and complicates the interpretation of anecdotal reports. Products with batch-specific certificates of analysis (COAs) from accredited third-party laboratories are the minimum standard for quality assurance. Standardized formulations with verified cannabinoid content — including minor cannabinoids like CBG, CBN, and CBC — are the gold standard.